Published in Oncotarget on March 07, 2017
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis (2010) 5.85
Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature (2005) 5.50
Molecular mechanisms of hepatocellular carcinoma. Hepatology (2008) 3.51
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18
Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation (1996) 2.04
Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol (2002) 1.84
Biology of hepatocellular carcinoma. Ann Surg Oncol (2008) 1.78
Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg (2004) 1.62
The role of vascular endothelial growth factor SNPs as predictive and prognostic markers for major solid tumors. Mol Cancer Ther (2009) 1.57
VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer (2004) 1.55
Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology (2002) 1.22
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer (2014) 1.11
Family history of liver cancer and hepatocellular carcinoma. Hepatology (2012) 1.09
Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma. Hepatol Res (2007) 1.07
Cigarette smoking and primary liver cancer: a population-based case-control study in US men. Cancer Causes Control (2007) 0.98
Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients. Hepatology (2007) 0.97
Hepatocellular carcinoma: the high-risk patient. J Clin Gastroenterol (2002) 0.97
The neurotransmitter dopamine modulates vascular permeability in the endothelium. J Mol Signal (2008) 0.96
Relationship between VEGFA polymorphisms and serum VEGF protein levels and recurrent spontaneous miscarriage. Hum Reprod (2013) 0.94
Vascular invasion in hepatocellular carcinoma: prevalence, determinants and prognostic impact. J Clin Gastroenterol (2014) 0.93
Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans. Mol Carcinog (2012) 0.92
Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. Future Oncol (2012) 0.88
Comparative proteomic profiles indicating genetic factors may involve in hepatocellular carcinoma familial aggregation. Cancer Sci (2012) 0.87
Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk. Mol Clin Oncol (2014) 0.87
Genetic variants of p21 and p27 and hepatocellular cancer risk in a Chinese Han population: a case-control study. Int J Cancer (2012) 0.86
The vascular endothelial growth factor-2549 insertion/deletion polymorphism is not associated with susceptibility to hepatocellular carcinoma in Chinese. DNA Cell Biol (2010) 0.84
Polymorphisms in the VEGFA promoter are associated with susceptibility to hepatocellular carcinoma by altering promoter activity. Int J Cancer (2013) 0.81
Correlation of genetic polymorphism of vascular endothelial growth factor gene with susceptibility to lung cancer. Cancer Gene Ther (2015) 0.80
Role of VEGF gene polymorphisms in the clinical outcome of non-small cell lung cancer. Genet Mol Res (2015) 0.80
The Association Between VEGF +936C/T and -634G/C Polymorphisms and Breast Cancer Susceptibility, Tumor Growth, and Metastases: Evidence From 20,728 Subjects. Cancer Invest (2015) 0.79
Discovery and validation of vascular endothelial growth factor (VEGF) pathway polymorphisms in esophageal adenocarcinoma outcome. Carcinogenesis (2015) 0.78
Predictive value of vascular endothelial growth factor polymorphisms on the clinical outcome of renal cell carcinoma patients. Oncol Lett (2014) 0.78
Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment. Genet Mol Res (2014) 0.77